Literature DB >> 1713672

Effects of the seleno-organic substance Ebselen in two different models of acute pancreatitis.

C Niederau1, K Ude, M Niederau, R Lüthen, G Strohmeyer, L D Ferrell, J H Grendell.   

Abstract

This study evaluated the effects of the seleno-organic substance Ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one] in two models of acute hemorrhagic and acute edematous pancreatitis. Ebselen is known to catalyze glutathione peroxidase-like reactions and to inhibit lipid peroxidation. Hemorrhagic pancreatitis was induced by feeding a choline-deficient, ethionine-supplemented (CDE) diet to mice for 66 h. Edematous pancreatitis was induced by 7-h subcutaneous injections of 50 micrograms/kg of cerulein in mice. Ebselen was given from the beginning of the CDE diet either as a subcutaneous injection of 100 mg/kg at 6-h intervals or was mixed in with the CDE diet to yield a daily dose of 100 mg/kg of Ebselen. In further experiments, Ebselen was given at various time intervals after the beginning of the CDE diet as subcutaneous injections of 100 mg/kg at 6-h intervals. In the cerulein model, Ebselen was given 5 min prior to each cerulein injection at doses from 10-500 mg/kg. Prophylactic administration of Ebselen given orally or subcutaneously significantly improved survival from 38.5% in the control group of saline-injected CDE-fed mice to 61.9 and 65.0%, respectively. Ebselen also reduced increases in serum amylase and pancreatic weight in the diet model. Therapeutic administration of Ebselen significantly increased survival only when injections were started 20 h after the beginning of the CDE diet (64%), but not when started after 40 h (44%). Similarly, increases in serum amylase and pancreatic weight due to the CDE diet were significantly reduced by Ebselen only when injections were started after 20 h but not when started after 40 h.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713672     DOI: 10.1097/00006676-199105000-00005

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  8 in total

Review 1.  The pharmacology of ebselen.

Authors:  M J Parnham; S Leyck; E Graf; E J Dowling; D R Blake
Journal:  Agents Actions       Date:  1991-01

Review 2.  Involvement of free radicals in the pathophysiology of chronic pancreatitis: potential of treatment with antioxidant and scavenger substances.

Authors:  C Niederau; H U Schultz; G Letko
Journal:  Klin Wochenschr       Date:  1991-12-15

Review 3.  Calcium and reactive oxygen species in acute pancreatitis: friend or foe?

Authors:  David M Booth; Rajarshi Mukherjee; Robert Sutton; David N Criddle
Journal:  Antioxid Redox Signal       Date:  2011-08-23       Impact factor: 8.401

4.  Alleviation of cell damage in experimental ANP in rats by administration of chondroitin-sulfate reduces.

Authors:  Zhongye He; Renxuan Guo; Chengyao Xie; Nan Liu; Yang Li; Wen Song
Journal:  Front Med China       Date:  2007-02

5.  Caerulein or taurocholate induced enzymatic and histologic alterations in the isolated perfused rat pancreas.

Authors:  R Mantke; D Schubert; C Röcken; I Paege; W Halangk; B Peters; H Lippert; H-U Schulz
Journal:  Langenbecks Arch Surg       Date:  2008-08-09       Impact factor: 3.445

6.  Evidence for early oxidative stress in acute pancreatitis. Clues for correction.

Authors:  J M Braganza; P Scott; D Bilton; D Schofield; C Chaloner; N Shiel; L P Hunt; T Bottiglieri
Journal:  Int J Pancreatol       Date:  1995-02

7.  Effects of C1-esterase inhibitor in three models of acute pancreatitis.

Authors:  C Niederau; R Brinsa; M Niederau; R Lüthen; G Strohmeyer; L D Ferrell
Journal:  Int J Pancreatol       Date:  1995-04

Review 8.  Murine Models of Acute Pancreatitis: A Critical Appraisal of Clinical Relevance.

Authors:  Pedro Silva-Vaz; Ana Margarida Abrantes; Miguel Castelo-Branco; António Gouveia; Maria Filomena Botelho; José Guilherme Tralhão
Journal:  Int J Mol Sci       Date:  2019-06-07       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.